PHA-57378

{{Short description|Chemical compound}}

{{Drugbox

| IUPAC_name = 2,7,8,9,10,11-hexahydro-1H-azepino[4,5-b][1,4]oxazino[2,3,4-hi]indole

| image = PHA-57378.svg

| image_class = skin-invert-image

| width = 240

| tradename =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 303798-94-9

| PubChem = 10198481

| ChemSpiderID = 8373981

| C=14 | H=16 | N=2 | O=1

| smiles = C1(OCC2)=C(N2C3=C4CCNCC3)C4=CC=C1

| StdInChI = 1S/C14H16N2O/c1-2-11-10-4-6-15-7-5-12(10)16-8-9-17-13(3-1)14(11)16/h1-3,15H,4-9H2

| StdInChIKey = KMVAXNRPZRSLSY-UHFFFAOYSA-N

}}

PHA-57378 is a drug which acts as an agonist at serotonin 5-HT₂ receptors,{{cite patent |country= WO |number= 2000064899 |status= application |title= Tetracyclic Azepinoindole Compounds as 5-HT Receptor Ligands |pubdate= 2 November 2000 |gdate= |fdate= April 20, 2000 |pridate= April 23, 1999 |inventor= Hester JB, Rogers BN, Jacobsen EJ, Ennis MD, Acker BA, Van der Velde SL, Frank KE |assign1= Pharmacia Upjohn Company |assign2= |class= |url= http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2000064899}} having a binding affinity of 4.1 nM at the 5-HT_2A subtype and 4.3 nM at 5-HT_2C. It has anxiolytic effects in animal studies.{{cite journal | vauthors = Ennis MD, Hoffman RL, Ghazal NB, Olson RM, Knauer CS, Chio CL, Hyslop DK, Campbell JE, Fitzgerald LW, Nichols NF, Svensson KA, McCall RB, Haber CL, Kagey ML, Dinh DM | display-authors = 6 | title = 2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists | journal = Bioorganic & Medicinal Chemistry Letters | volume = 13 | issue = 14 | pages = 2369–72 | date = July 2003 | pmid = 12824036 | doi = 10.1016/S0960-894X(03)00403-7 }}